VSports app下载 - Comparison of six different calprotectin assays for the assessment of inflammatory bowel disease
- PMID: 24918006
- PMCID: V体育ios版 - PMC4040805
- DOI: 10.1177/2050640613518201
"VSports" Comparison of six different calprotectin assays for the assessment of inflammatory bowel disease
Abstract
Background and objectives: Faecal calprotectin is a valuable noninvasive marker for inflammatory bowel disease (IBD) VSports手机版. The aim of our study was to determine the correlation between six different calprotectin assays and compare their performance for diagnosis and follow up of IBD. .
Methods: Thirty-one patients with suspected IBD and 31 patients in follow up were included. We determined calprotectin by means of three rapid immmunochromatographic tests, two enzyme-linked immunosorbent assays, and one automated fluoroimmunoassay. Results were correlated with endoscopic and histological findings. V体育安卓版.
Results: Although all methods correlated significantly, slopes and intercepts differed extensively, with up to 5-fold quantitative differences between assays. Sensitivity and specificity for diagnosis of IBD were 82-83 and 84-89%, respectively. For follow up, sensitivity in detecting mild ulcerative colitis was 71-100%. In moderate-to-severe ulcerative colitis, sensitivity was 100% for all assays. Specificity was 67-86% in both subgroups V体育ios版. In Crohn's disease, only moderate-to-severe disease could be differentiated from remission, with sensitivity 83-86% and specificity 75% for all tests. .
Conclusions: All calprotectin assays showed comparable clinical performance for diagnosis of IBD. For follow up, performance was acceptable, except for mild Crohn's disease VSports最新版本. Because of the large quantitative differences, further efforts are needed to standardize calprotectin assays. .
Keywords: Calprotectin; Crohn’s disease; diagnosis; follow up; inflammatory bowel disease; ulcerative colitis. V体育平台登录.
Figures (VSports在线直播)
 
              
              
              
              
                
                
                References
- 
    - Bernstein CN, Fried M, Krabshuis JH, et al. World Gastroenterology Organization practice guidelines for the diagnosis and managment of IBD in 2010. Inflamm Bowel Dis 2010; 16: 112–114 - PubMed
 
- 
    - Centre for Evidence-based Purchasing. Evidence review: value of calprotectin in screening out irritable bowel syndrome, CEP09026. London: NHS Purchasing and Supply Agency, 2009.
 
- 
    - De Vos M, Dewit O, D’Haens G, et al. Fast and sharp decrease in calprotectin predicts remission by infliximab in anti-TNF naïve patients with ulcerative colitis. J Crohns Colitis 2012; 6: 557–562 - PubMed
 
V体育平台登录 - LinkOut - more resources
- Full Text Sources
- Other Literature Sources
 
        